134 related articles for article (PubMed ID: 19635201)
21. Effect of gefitinib challenge to initial treatment with non-small cell lung cancer.
Chen X; Li W; Hu X; Geng Y; Wang R; Yin Y; Shu Y
Biomed Pharmacother; 2011 Dec; 65(8):542-6. PubMed ID: 21840160
[TBL] [Abstract][Full Text] [Related]
22. [Gefitinib in the treatment of male patients with advanced non-small-cell lung cancer].
Wang B; Zhang XR; Chu DT
Zhonghua Zhong Liu Za Zhi; 2007 Jul; 29(7):549-51. PubMed ID: 18069641
[TBL] [Abstract][Full Text] [Related]
23. Phase II trial of sequential gefitinib after minor response or partial response to chemotherapy in Chinese patients with advanced non-small-cell lung cancer.
Xu JM; Han Y; Li YM; Zhao CH; Wang Y; Paradiso A
BMC Cancer; 2006 Dec; 6():288. PubMed ID: 17173694
[TBL] [Abstract][Full Text] [Related]
24. Risk factors for interstitial lung disease and predictive factors for tumor response in patients with advanced non-small cell lung cancer treated with gefitinib.
Takano T; Ohe Y; Kusumoto M; Tateishi U; Yamamoto S; Nokihara H; Yamamoto N; Sekine I; Kunitoh H; Tamura T; Kodama T; Saijo N
Lung Cancer; 2004 Jul; 45(1):93-104. PubMed ID: 15196739
[TBL] [Abstract][Full Text] [Related]
25. First-line gefitinib treatment for patients with advanced non-small cell lung cancer with poor performance status.
Lee YJ; Kim HT; Han JY; Yun T; Lee GK; Kim HY; Sung JH; Lee JS
J Thorac Oncol; 2010 Mar; 5(3):361-8. PubMed ID: 20107420
[TBL] [Abstract][Full Text] [Related]
26. Phase II study of erlotinib for acquired resistance to gefitinib in patients with advanced non-small cell lung cancer.
Horiike A; Yamamoto N; Tanaka H; Yanagitani N; Kudo K; Ohyanagi F; Ono A; Naito T; Murakami H; Horai T; Nishio M
Anticancer Res; 2014 Apr; 34(4):1975-81. PubMed ID: 24692734
[TBL] [Abstract][Full Text] [Related]
27. [Gefitinib in the treatment of advanced non-small cell lung cancer with brain metastasis].
Wu C; Li LY; Wang MZ; Zhang L; Zhang XT; Zhong W; Wang SL; Wang HZ
Zhonghua Zhong Liu Za Zhi; 2007 Dec; 29(12):943-5. PubMed ID: 18478938
[TBL] [Abstract][Full Text] [Related]
28. [Evaluation of efficacy and safety of ZD1839 as monotherapy in Chinese patients with advanced non-small cell lung cancer].
Wang MZ; Li LY; Wang SL; Zhang XT; Zhong W; Zhang L; Li JR
Zhonghua Nei Ke Za Zhi; 2008 Apr; 47(4):291-5. PubMed ID: 18843952
[TBL] [Abstract][Full Text] [Related]
29. Retrospective analysis of the predictive factors associated with the response and survival benefit of gefitinib in patients with advanced non-small-cell lung cancer.
Kaneda H; Tamura K; Kurata T; Uejima H; Nakagawa K; Fukuoka M
Lung Cancer; 2004 Nov; 46(2):247-54. PubMed ID: 15474673
[TBL] [Abstract][Full Text] [Related]
30. [Efficacy and safety of gefitinib in maintenance therapy for patients with advanced non-small cell lung cancer].
Wang MZ; Zhong W; Zhang L; Li LY; Wang SL; Li JR; Zhang XT
Zhonghua Zhong Liu Za Zhi; 2008 Mar; 30(3):221-4. PubMed ID: 18756941
[TBL] [Abstract][Full Text] [Related]
31. Smoking history and prior surgical resection predict sensitivity to gefitinib in advanced non-small-cell lung cancer.
Matsuura K; Kudoh S; Yoshimura N; Kimura T; Mitsuoka S; Hirata K; Yoshikawa J; Iwao H
Osaka City Med J; 2006 Jun; 52(1):1-8. PubMed ID: 16986358
[TBL] [Abstract][Full Text] [Related]
32. Randomized phase II study of gefitinib versus erlotinib in patients with advanced non-small cell lung cancer who failed previous chemotherapy.
Kim ST; Uhm JE; Lee J; Sun JM; Sohn I; Kim SW; Jung SH; Park YH; Ahn JS; Park K; Ahn MJ
Lung Cancer; 2012 Jan; 75(1):82-8. PubMed ID: 21684626
[TBL] [Abstract][Full Text] [Related]
33. Phase II trial of gefitinib in pretreated Chinese women with advanced non-small-cell lung cancer.
Deng J; Fang WJ; Zhang XC; Wu DP; Fang HM; Chen J; Qian J; Mou HB; Chu BB; Xu N; Teng LS
Med Oncol; 2012 Jun; 29(2):595-9. PubMed ID: 21399997
[TBL] [Abstract][Full Text] [Related]
34. Tumor response and health-related quality of life in clinically selected patients from Asia with advanced non-small-cell lung cancer treated with first-line gefitinib: post hoc analyses from the IPASS study.
Wu YL; Fukuoka M; Mok TS; Saijo N; Thongprasert S; Yang JC; Chu DT; Yang JJ; Rukazenkov Y
Lung Cancer; 2013 Aug; 81(2):280-7. PubMed ID: 23540718
[TBL] [Abstract][Full Text] [Related]
35. EGFR mutations in patients with non small-cell lung cancer in Bulgaria and treatment with gefitinib.
Damyanov D; Koynov K; Naseva E; Bichev S
J BUON; 2015; 20(1):136-41. PubMed ID: 25778308
[TBL] [Abstract][Full Text] [Related]
36. Differential efficacy of gefitinib across age groups in treatment of advanced lung adenocarcinoma.
Wang H; Zhang G; Li P; Yan X; Wang Q; Zhu H; Qi G; Fan Q; Ma Z
Pharmazie; 2012 Jan; 67(1):80-5. PubMed ID: 22393836
[TBL] [Abstract][Full Text] [Related]
37. Gefitinib as a last treatment option for non-small-cell lung cancer: durable disease control in a subset of patients.
Haringhuizen A; van Tinteren H; Vaessen HF; Baas P; van Zandwijk N
Ann Oncol; 2004 May; 15(5):786-92. PubMed ID: 15111348
[TBL] [Abstract][Full Text] [Related]
38. Single-agent gefitinib in patients with untreated advanced non-small-cell lung cancer and poor performance status: a Minnie Pearl Cancer Research Network Phase II Trial.
Spigel DR; Hainsworth JD; Burkett ER; Burris HA; Yardley DA; Thomas M; Jones SF; Dickson NR; Scullin DC; Bradof JE; Rubinsak JR; Brierre JE; Greco FA
Clin Lung Cancer; 2005 Sep; 7(2):127-32. PubMed ID: 16179100
[TBL] [Abstract][Full Text] [Related]
39. [Classification and regression tree analysis of clinical patterns that predict survival in 127 Chinese patients with advanced non-small cell lung cancer treated by gefitinib who failed to previous chemotherapy].
Wang Z; Guo J; Wang Y; Liu Y; Yang J
Zhongguo Fei Ai Za Zhi; 2011 Sep; 14(9):699-703. PubMed ID: 21924034
[TBL] [Abstract][Full Text] [Related]
40. [Erlotinib in the treatment of advanced non-small-cell lung cancer (NSCLC)].
Tang CH; Liu XQ; Gao HJ; Li JJ; Guo WF; Li XY; Wang WX; Liu B; Qu LL; Wang WW
Zhonghua Zhong Liu Za Zhi; 2010 Feb; 32(2):143-7. PubMed ID: 20403247
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
